The firm is discontinuing its CHIRON and THETIS trials after lackluster data and is planning for potential third-party deals and workforce layoffs.
A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).
The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.